cfDNA–STING pathway as a marker in atopic dermatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, cross-sectional comparison of 40 adults with atopic dermatitis and 40 age- and sex-matched healthy controls. Researchers will collect peripheral blood from all participants to quantify plasma cell-free DNA (cfDNA) using fluorometric assays and will perform 4 mm punch biopsies of active lesional skin in a subset of patients. Skin samples will undergo immunofluorescence to characterize CD68+ macrophage infiltration and STING protein expression and co-localization. Clinical dermatologic assessments will be used to correlate cfDNA and tissue STING signatures with moderate versus severe disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older
* Confirmed diagnosis of Atopic Dermatitis

Exclusion Criteria:

* Use of systemic immunosuppressants, systemic corticosteroids, or biological agents within 4 weeks prior to enrollment
* Use of topical treatments within 2 weeks prior to enrollment

Where it's running

• Zhongda Hospital, Southeast University
  Nanjing, Jiangsu, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing a new hydrogel for treating mild to moderate eczema

  This study is testing a new hydrogel called zabalafin to see if it helps people with mild to moderate eczema feel better compared to a placebo.

  Recruiting at 12 sites Phase 2 Alphyn Biologics · Brookvale, New South Wales and 11 other locations · NCT06855745

• Herbal ointment for treating atopic dermatitis

  This study is testing a herbal ointment made from a plant to see if it can help people with atopic dermatitis feel better.

  Recruiting Phase 2/3 En Chu Kong Hospital · New Taipei City · NCT06850311

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Skin structure in atopic dermatitis patients treated with nemolizumab assessed by reflectance confocal microscopy

  This study tests whether nemolizumab changes skin structure in adults with moderate-to-severe atopic dermatitis using a noninvasive imaging method.

  Recruiting Hôpitaux Drôme Nord · Romans-sur-Isère, Drôme · NCT07730788

• Global Health Look at Atopic Dermatitis

  A worldwide, multicenter study tests how people with atopic dermatitis access care and treat it, using data from routine medical records.

  Recruiting University of Zurich · Zurich · NCT07659756

• Impact of dietary salt on skin sodium and inflammatory skin disease

  We’re testing whether lowering salt and taking salt tablets changes skin sodium and symptoms in eczema and psoriasis.

  Recruiting at 2 sites Phase 4 University of California, San Francisco · San Francisco, California and 1 other locations · NCT07487831

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.